Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute

Neurotrope, Inc. (NASDAQ: NTRP) announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.

Intuitive Venture PartnersFebruary 4, 2019neurotrope, 2019

Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Neurotrope, Inc. (NASDAQ: NTRP), announces that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018.

Intuitive Venture PartnersSeptember 27, 2018neurotrope, 2018

Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome

Neurotrope Inc. (NASDAQ: NTRP) is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").

pharmaceutical, alzheimersIntuitive Venture PartnersSeptember 5, 2018neurotrope, 2018

Neurotrope Provides Business Update and Reports Second Quarter 2018 Financial Results

Neurotrope, Inc. (NASDAQ: NTRP) today provided a business update outlining recent clinical development progress and other noteworthy events that occurred subsequent to the end of the quarter and unaudited financial results for the quarter ended June 30, 2018.

Intuitive Venture PartnersAugust 13, 2018neurotrope, 2018

Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer’s Patients

Neurotrope, Inc. (NASDAQ: NTRP) announces completion of the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer’s disease.

Intuitive Venture PartnersMay 7, 2018neurotrope, 2018